Cargando…
Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status
PURPOSE: To investigate the absorption of synthetic cyanocobalamin and natural occurring hydroxocobalamin in populations with low and normal cobalamin (vitamin B12) status. METHODS: We included adults with low (n = 59) and normal (n = 42) cobalamin status and measured the change in serum holotransco...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267412/ https://www.ncbi.nlm.nih.gov/pubmed/29038891 http://dx.doi.org/10.1007/s00394-017-1553-5 |
_version_ | 1783376069563252736 |
---|---|
author | Greibe, Eva Mahalle, Namita Bhide, Vijayshri Heegaard, Christian W. Naik, Sadanand Nexo, Ebba |
author_facet | Greibe, Eva Mahalle, Namita Bhide, Vijayshri Heegaard, Christian W. Naik, Sadanand Nexo, Ebba |
author_sort | Greibe, Eva |
collection | PubMed |
description | PURPOSE: To investigate the absorption of synthetic cyanocobalamin and natural occurring hydroxocobalamin in populations with low and normal cobalamin (vitamin B12) status. METHODS: We included adults with low (n = 59) and normal (n = 42) cobalamin status and measured the change in serum holotranscobalamin (ΔholoTC) before and after 2 day administration of different doses of cyanocobalamin and hydroxocobalamin (CobaSorb test). In the low status group, the test was performed using a cross-over design with identical doses of both cobalamin forms (1.5, 3, and 6 µg, respectively). In the normal status group, the test was performed with either 3, 6, and 9 µg cyanocobalamin (n = 28), or with 9 µg cyanocobalamin and 9 µg hydroxocobalamin (n = 14). RESULTS: In both groups, median ΔholoTC (pmol/L) was higher after intake of cyanocobalamin compared to (hydroxocobalamin) [low status: 1.5 µg: 19 (6); 3 µg: 23 (7); 6 µg: 30 (14); normal status: 9 µg: 30 (13) pmol/L]. Independent of B12 form, no difference was observed in ΔholoTC between those receiving 1.5 and 3 µg in the low status group or 6 and 9 µg cyanocobalamin in the normal status group. However, in both groups, administration of 6 µg cobalamin resulted in a significant higher ΔholoTC than did 3 µg [low status: p = 0.02 (0.009) for cyanocobalamin (hydroxocobalamin); normal status: p = 0.03 for cyanocobalamin]. CONCLUSIONS: Administration of cyanocobalamin resulted in a more than twofold increase in holoTC in comparison with hydroxocobalamin. The absorptive capacity was reached only by doses above 3 µg cobalamin. Our results underscore the importance of using the same form of cobalamin when comparing uptake under different conditions. CLINICAL TRIAL REGISTRY NUMBER: NCT02832726 at https://clinicaltrials.gov and 2016/09/012147 at Clinical Trials Registry India. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00394-017-1553-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6267412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-62674122018-12-11 Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status Greibe, Eva Mahalle, Namita Bhide, Vijayshri Heegaard, Christian W. Naik, Sadanand Nexo, Ebba Eur J Nutr Original Contribution PURPOSE: To investigate the absorption of synthetic cyanocobalamin and natural occurring hydroxocobalamin in populations with low and normal cobalamin (vitamin B12) status. METHODS: We included adults with low (n = 59) and normal (n = 42) cobalamin status and measured the change in serum holotranscobalamin (ΔholoTC) before and after 2 day administration of different doses of cyanocobalamin and hydroxocobalamin (CobaSorb test). In the low status group, the test was performed using a cross-over design with identical doses of both cobalamin forms (1.5, 3, and 6 µg, respectively). In the normal status group, the test was performed with either 3, 6, and 9 µg cyanocobalamin (n = 28), or with 9 µg cyanocobalamin and 9 µg hydroxocobalamin (n = 14). RESULTS: In both groups, median ΔholoTC (pmol/L) was higher after intake of cyanocobalamin compared to (hydroxocobalamin) [low status: 1.5 µg: 19 (6); 3 µg: 23 (7); 6 µg: 30 (14); normal status: 9 µg: 30 (13) pmol/L]. Independent of B12 form, no difference was observed in ΔholoTC between those receiving 1.5 and 3 µg in the low status group or 6 and 9 µg cyanocobalamin in the normal status group. However, in both groups, administration of 6 µg cobalamin resulted in a significant higher ΔholoTC than did 3 µg [low status: p = 0.02 (0.009) for cyanocobalamin (hydroxocobalamin); normal status: p = 0.03 for cyanocobalamin]. CONCLUSIONS: Administration of cyanocobalamin resulted in a more than twofold increase in holoTC in comparison with hydroxocobalamin. The absorptive capacity was reached only by doses above 3 µg cobalamin. Our results underscore the importance of using the same form of cobalamin when comparing uptake under different conditions. CLINICAL TRIAL REGISTRY NUMBER: NCT02832726 at https://clinicaltrials.gov and 2016/09/012147 at Clinical Trials Registry India. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00394-017-1553-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-10-16 2018 /pmc/articles/PMC6267412/ /pubmed/29038891 http://dx.doi.org/10.1007/s00394-017-1553-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Contribution Greibe, Eva Mahalle, Namita Bhide, Vijayshri Heegaard, Christian W. Naik, Sadanand Nexo, Ebba Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status |
title | Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status |
title_full | Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status |
title_fullStr | Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status |
title_full_unstemmed | Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status |
title_short | Increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status |
title_sort | increase in circulating holotranscobalamin after oral administration of cyanocobalamin or hydroxocobalamin in healthy adults with low and normal cobalamin status |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267412/ https://www.ncbi.nlm.nih.gov/pubmed/29038891 http://dx.doi.org/10.1007/s00394-017-1553-5 |
work_keys_str_mv | AT greibeeva increaseincirculatingholotranscobalaminafteroraladministrationofcyanocobalaminorhydroxocobalamininhealthyadultswithlowandnormalcobalaminstatus AT mahallenamita increaseincirculatingholotranscobalaminafteroraladministrationofcyanocobalaminorhydroxocobalamininhealthyadultswithlowandnormalcobalaminstatus AT bhidevijayshri increaseincirculatingholotranscobalaminafteroraladministrationofcyanocobalaminorhydroxocobalamininhealthyadultswithlowandnormalcobalaminstatus AT heegaardchristianw increaseincirculatingholotranscobalaminafteroraladministrationofcyanocobalaminorhydroxocobalamininhealthyadultswithlowandnormalcobalaminstatus AT naiksadanand increaseincirculatingholotranscobalaminafteroraladministrationofcyanocobalaminorhydroxocobalamininhealthyadultswithlowandnormalcobalaminstatus AT nexoebba increaseincirculatingholotranscobalaminafteroraladministrationofcyanocobalaminorhydroxocobalamininhealthyadultswithlowandnormalcobalaminstatus |